CSH Technology: ACQUITY CSH Columns Applications Notebook

Similar documents
viridis Columns Bringing a New Dimension to SFC Combining state-of-the-art media manufacturing with industry leading column technology, Viridis

ANALYSIS OF BASIC COMPOUNDS

[ Care and Use Manual ]

Put the. C18 aside. and take a look... Reasons. to try the. NEW Gemini C6-Phenyl

DEMONSTRATING SUPERIOR LINEARITY: THE ACQUITY UPLC PHOTODIODE ARRAY DETECTOR

Determination of Pharmaceuticals in Environmental Samples

ultimate efficiency unleashed [ Cortecs 1.6 µm columns ]

Setting the Standard for ph Method Development

The Standard for ph Method Development

Determination of Verapamil Hydrochloride Purity Using the Acclaim PA Column

ApplicationNOTE ULTRA TRACE ANALYSIS OF DIOXINS AND FURANS IN HUMAN ADIPOSE TISSUE USING SFE-LC EXTRACTION/CLEANUP AND THE WATERS AUTOSPEC ULTIMA NT

1.7µm Fortis C18 UHPLC Columns

mau 200 ph min

Semi-Targeted Screening of Pharmaceutically- Related Contaminants in the Thames Tideway using LC-HRMS

A Workflow Approach for the Identification and Structural Elucidation of Impurities of Quetiapine Hemifumarate Drug Substance

Simultaneous Determination of Pharmaceutical Peptides and Acetate Counterions by HPLC Using a Mixed-Mode Weak Anion-Exchange Column

Gemini. Second-Generation TWIN-NX Technology. TWIN (Two-In-One) Technology. U.S. Patent No. 7, 563, 367 Setting the Standard for ph Method Development

Setting the Standard for ph Method Development

APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEY WORDS. Simultaneous high-throughput screening of melamine (MEL) and cyanuric acid (CYA).

[ OSTRO PASS-THROUGH SAMPLE PREPARATION PRODUCT ] The Simpler Way to Cleaner Samples

Rapid method development to study plasma stability of diverse pharmaceutical compounds using Rapid Resolution LC and triple quadrupole MS

Simultaneous, Fast Analysis of Melamine and Analogues in Pharmaceutical Components Using Q Exactive - Benchtop Orbitrap LC-MS/MS

surpass all possibilities [ Cortecs 2.7 µm columns ]

ApplicationNOTE Abstract

IN QUALITATIVE ANALYSIS,

Multiple Fragmentation Methods for Small Molecule Characterization on a Dual Pressure Linear Ion Trap Orbitrap Hybrid Mass Spectrometer

Analgesics / Cough 1 & Cold Medicine Ingredients

A Unique, New, Multipurpose Sorbent Engineered for Reversed-Phase SPE

APPLICATIONS TN HPLC Conditions. Lux Cellulose-1 Cellulose tris(3,5-dimethylphenylcarbamate)

4.1 MATERIALS 4.2 EQUIPMENTS

Yun W. Alelyunas, Mark D. Wrona, Russell J. Mortishire-Smith, Nick Tomczyk, and Paul D. Rainville Waters Corporation, Milford, MA, USA INTRODUCTION

HPLC COLUMNS VaRian, inc. Pursuit XRs EXtRa REsolution. Ma XiMuM lifetime. ultimate PERfoRMancE.

APPLICATIONS TN Lux Cellulose-2 or -4 Cellulose tris (3-chloro-4-methylphenylcarbamate) or (4-chloro-3-methylphenylcarbamate)

Separation of Structurally Similar Steroids on HALO C18 and PFP

Zirconia-Based Phases as a Powerful Complement to Silica-Based Phases for LC and LC-MS under Non-extreme Mobile Phase Conditions

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

The Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity

Developing a fast, generic method for rapid resolution LC with quadrupole MS detection. Application Note

Key Words Q Exactive Focus, Orbitrap, veterinary drugs, small molecule HRAM quantitation, small molecule HRAM screening, UHPLC, vdia

The Analysis of Organic Acids in Foods and Beverages Using Reversed Phase HPLC

columns Acclaim Mixed-Mode WCX-1 for Separating Basic Molecules

FORENSIC TOXICOLOGY SCREENING APPLICATION SOLUTION

Determination of the Composition of Natural Products by HPLC with Charged Aerosol Detection. Introduction. Black Cohosh. Corona Detector Parameters

A Quality by Design (QbD) Based Method Development for the Determination of Impurities in a Peroxide Degraded Sample of Ziprasidone

LC-MS/MS Method for the Determination of Diclofenac in Human Plasma

Ultrasensitive EPA Method 1694 with the Agilent 6460 LC/MS/MS with Jet Stream Technology for Pharmaceuticals and Personal Care Products in Water

Sensitive HPLC Method for Triterpenoid Analysis Using Charged Aerosol Detection with Improved Resolution

ColumnsAcclaim PolarAdvantage II (PA2) HPLC Columns

Analysis of Serum 17-Hydroxyprogesterone, Androstenedione, and Cortisol by UPLC-MS/MS for Clinical Research

Metoprolol and Select Impurities Analysis Using a Hydrophilic Interaction Chromatography Method with Combined UV and Charged Aerosol Detection

Quick Guide QUICK GUIDE. Activity 1: Determine the Reaction Rate in the Presence or Absence of an Enzyme

Determination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry

Developing Analytical Chromatographic Methods for Pharmaceutical Stability Investigations

Gemini-NX Performance paired with Axia Technology

High Performance Liquid Chromatography. Table 1: Allowed HPLC Adjustment of USP <621> and EP <2.2.46>

CHROMABOND HLB. Introduction. Advantages of CHROMABOND HLB. Technical data

Accelerated Solvent Extraction GC-MS Analysis and Detection of Polycyclic Aromatic Hydrocarbons in Soil

ApplicationNOTE A STUDY OF THE ANALYSIS OF POLYBROMINATED DIPHENYL ETHER FLAME RETARDANTS BY GC/MS/MS. Introduction. Materials and Methods

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

UPLC Method Development and Validation

Your Reversed Phase Method

Revision Bulletin Official April 1, 2014 Alprazolam 1

Routine MS Detection for USP Chromatographic Methods

Rapid, Reliable Metabolite Ratio Evaluation for MIST Assessments in Drug Discovery and Preclinical Studies

IDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)

penta-hilic UHPLC COLUMNS

HPLC Determination of Antidepressants and their Metabolites in Plasma

Analyzing Residual Solvents in Pharmaceutical Products Using GC Headspace with Valve-and-Loop Sampling

Fast methods for the determination of ibuprofen in drug products

Streamlining the Analysis of Oral Contraceptives Using the ACQUITY UPLC H-Class System

Automating Method Development with an HPLC System Optimized for Scouting of Columns and Eluents

EPA Method 1694: Analysis of Pharmaceuticals and Personal Care Products in Water

2017 Source of Foreign Income Earned By Fund

Welcome to our E-Seminar: Choosing HPLC Columns for Faster Analysis Smaller and Faster

[ Care and Use Manual ]

Utility of H-SRM to Reduce Matrix Interference in Food Residue Analysis of Pesticides by LC-MS/MS Using the TSQ Quantum Discovery

APPLICATIONS TN Peptide Purification Method Development: Application for the Purification of Bivalirudin. Introduction

It s hot! ZIC -chilic

Next Generation of Phenyl Columns. Chromatography Products.

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

[application note] ACQUITY UPLC/SQD ANALYSIS OF POLYMER ADDITIVES. Peter J. Lee, and Alice J. Di Gioia, Waters Corporation, Milford, MA, U.S.A.

Q-TOF PREMIER DYNAMIC RANGE ENHANCEMENT AND ACCURATE MASS MEASUREMENT PERFORMANCE

A Study of Stability, Robustness and Time Efficiency of a New HPLC and a New Tandem MS

Improved Extraction of THC and its Metabolites from Oral Fluid Using Oasis PRiME HLB Solid Phase Extraction (SPE) and a UPLC CORTECS C 18

New On-Line High-Pressure Electrolytic Eluent Generators for Ion Chromatography

Extraction of Aflatoxins and Ochratoxin from Dried Chili Using ISOLUTE. Myco Prior to LC-MS/MS Analysis

An Evaluation of Various High-Resolution, Accurate-Mass Scan Modes for In Vitro Drug Discovery Screening

penta-hilic UHPLC COLUMNS

DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR IN-VIVO STUDY OF DICLOFENAC POTASSIUM

Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

Frank Steiner, Michael Heidorn, and Markus M. Martin Thermo Fisher Scientific, Germering, Germany

Appendix B: Detailed tables showing overall figures by country and measure

Thermo Scientific Accucore XL HPLC Columns. Technical Manual

Key Words Q Exactive, Accela, MetQuest, Mass Frontier, Drug Discovery

Rapid Quan/Qual Metabolic Stability Analysis with Online Oxidative Metabolism Synthesis

The Secrets of Rapid HPLC Method Development. Choosing Columns for Rapid Method Development and Short Analysis Times

Eliminating Unwanted Variability in LC Methods: More Uptime, More Sample Throughput

Conc n of A OAs present (um) Conc n of B OAs present (um)

NUCLEOSHELL core-shell silica for HPLC

Transcription:

CS Technology: ACQUITY CS Columns Applications otebook

List of compounds analyzed using csh columns Lit Code Title Page WA Acetaminophen Impurities WA Acids, Bases, and eutrals WA Aromatic Acids WA Basic Drugs WA Beta Blockers WA Buproprion ydrochloride (Wellbutrin) in Extended Release Tablets 7 WA ozapine Impurities 8 WA Food Additives 9 WA Formic and Acetic Acid 0 WA8 Mirtazapine Impurities WA7 onsteroidal Anti-Inflammatory Drugs (SAIDS) WA9 rganic Acids WA8 Paroxetine Impurities WA9 Paroxetine Isomers WA0 Pharmaceutical Test Mix WA7 Statin Drugs 7 WA Sulfa Drugs 8 WA Tricyclic Antidepressants 9 WA0 Veterinary Drugs 0

ACQUITY CS WA Analysis of Acetaminophen Impurities Using ACQUITY CS Columns LC CDITIS ACQUITY CS Fluoro-Phenyl,. x 0 mm,.7 μm Part umber: 800 Mobile Phase A: 0.% acetic acid in Mobile Phase B: acetonitrile Gradien: Time Flow (min) (ml/min) %A %B Curve Initial 0. 98 Initial.00 0. 0 0.0 0. 0 0. 0. 98.0 0. 98 μl Column Temperature: 0 C Weak eedle Wash: Strong eedle Wash: Filter Time Constant: 9/ /acetonitrile 9/ acetonitrile/ UV @ 70 nm 0 points/sec 0. sec ACQUITY UPLC System with -Aminophenol -itrophenol Acetaminophen -Chloroacetanilide 0.0. -Aminophenol ( mg/ml). Acetaminophen (0. mg/ml). -itrophenol ( mg/ml). -Chloroacetanilide ( mg/ml) 0.0 0-0.0 0. 0. 0. 0.8.0....8.0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

LC CDITIS Columns: ACQUITY CS C 8,. x 0 mm,.7 μm Part umber: 8009 ACQUITY CS Phenyl-exyl,. x 0 mm,.7 μm Part umber: 8000 ACQUITY CS Fluoro-Phenyl,. x 0 mm,.7 μm Part umber: 800 Mobile Phase A: 0.% formic acid in (p ~.7) Mobile Phase B: Gradient Table: acetonitrile Time (min) Flow (ml/min) Analysis of Acids, Bases, and eutrals Using ACQUITY CS Columns %A %B Curve Imipramine S Amitriptyline ACQUITY CS WA Initial 0. 9 Initial.00 0. 9.0 0. 9.0 0. 9 -Pyrenesulfonic acid Flavone μl (PL) /7 methanol/ C Column Temperature: 0 C Fenoprofen Weak eedle Wash: 9/ /acetonitrile Strong eedle Wash: 9/ acetonitrile/ UV @ nm 0 points/sec C Filter Time Constant: 0. sec ACQUITY UPLC System with column manager Diclofenac ctanophenone and detector 0. 0.0 0. ACQUITY CS C8 7. Imipramine (00 µg/ml). Amitriptyline (00 µg/ml). -Pyrenesulfonic acid (0 µg/ml) 0. ACQUITY CS Phenyl-exyl 0.0 7. Flavone (0 µg/ml). Fenoprofen (00 µg/ml). Diclofenac (00 µg/ml) 7. ctanophenone (00 µg/ml) 0. 0. 0.0 ACQUITY CS Fluoro-Phenyl 7 0..0.0.0.80 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA Analysis of Aromatic Acids Using ACQUITY CS Columns LC CDITIS ACQUITY CS C 8,. x 0 mm,.7 μm Part umber: 8009 Mobile Phase A: 0.% acetic acid in Mobile Phase B: acetonitrile Time Flow (min) (ml/min) %A %B Curve Sample Concentration: 0 µg/ml each Initial 0. 98 Initial.00 0. 0 0.0 0. 0 0. 0. 98.00 0. 98 μl Column Temperature: 0 C Weak eedle Wash: Strong eedle Wash: Filter Time Constant: 9/ /acetonitrile 9/ acetonitrile/ UV @ 80 nm 0 points/sec 0. sec ACQUITY UPLC System with C Protocatechuic acid C -ydroxybenzoic acid C C Vanillic acid C C C C Syringic acid Salicylic acid,-dihydroxyphenylacetic acid (DPAC) C C,-Dichlorophenoxyacetic acid (Weed B Gon) 0.0. Protocatechuic acid.,-dihydroxyphenylacetic acid (DPAC) 0.. -ydroxybenzoic acid. Vanillic acid. Syringic acid 0. 0.08. Salicylic acid 7.,-Dichlorophenoxyacetic acid (Weed B Gon) 0.0 7 0.0 0..0..0..0..0..0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

LC CDITIS Part umber: 8000 ACQUITY CS Phenyl-exyl,. x 0 mm,.7 μm Mobile Phase A: 0 mm ammonium formate, p Mobile Phase B: acetonitrile μl Column Temperature: 0 C Weak eedle Wash: Strong eedle Wash: Filter Time Constant: Time (min) 9/ /acetonitrile 9/ acetonitrile/ UV @ 0 nm 0 points/sec 0. sec ACQUITY UPLC System with ACQUITY UPLC PDA Flow (ml/min) %A %B Curve Initial 0. 9 Initial.00 0..0 0.. 0. 9.0 0. 9 Analysis of Basic Drugs Using ACQUITY CS Columns C C C -aminopyrazine Quinine Labetalol C Verapamil C C S Pindolol Diltiazem Amitriptyline C ACQUITY CS WA 0.0 7. -aminopyrazine ( μg/ml). Pindolol (0 μg/ml) 0.. Quinine (0 μg/ml) 0. 8 9. Quinine impurity. Labetalol (0 μg/ml). Diltiazem impurity 7. Diltiazem ( μg/ml) 0.08 8. Verapamil (0 μg/ml) 9. Amitriptyline ( μg/ml) 0.0 0.0 0..0..0..0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA Analysis of Beta Blockers Using ACQUITY CS Columns LC CDITIS ACQUITY CS Phenyl-exyl,. x 0 mm,.7 μm Part umber: 8000 Mobile Phase A: 0 mm ammonium formate, p Mobile Phase B: acetonitrile Time Flow (min) (ml/min) %A %B Curve Initial 0. 9 Initial.00 0. 8.0 0. 8. 0. 9.0 0. 9 μl Sample Concentration: 0 µg/ml each Column Temperature: 0 C Weak eedle Wash: Strong eedle Wash: Filter Time Constant: 9/ /acetonitrile 9/ acetonitrile/ UV @ 80 nm 0 points/sec 0. sec ACQUITY UPLC System with C Atenolol Metoprolol Pindolol Labetalol xprenolol Propranolol 0.0 0.08 0.0. Atenolol. Pindolol. Metoprolol. xprenolol. Labetalol 0.0 0.0. Propranolol 0.0 0..0..0..0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

LC CDITIS Part umber: 8009 Mobile Phase A: Mobile Phase B: Mobile Phase C: Analysis of Bupropion ydrochloride (Wellbutrin) in Extended Release TabletsUsing ACQUITY CS Columns ACQUITY CS C 8,. x 0 mm,.7 μm acetonitrile % formic acid in Time (min) Flow (ml/min) %A %B %C Curve Sample Preparation ProcedurE Ten extended release tablets (each containing 00 mg bupropion hydrochloride) were homogenized in 0 ml of 0/0 methanol/ to give 0 mg/ml of bupropion hydrochloride. The sample was then centrifuged at 000 rpm for 0 minutes. The supernatant was then diluted to 0.0 mg/ml in and filtered through a 0. µm PVDF syringe filter prior to injection. ACQUITY CS WA Initial 0.9 90 Initial.00 0.9 0 9.0 0.9 0 9. 0.9 90.00 0.9 90 μl Sample Concentration: 0 µg/ml Bupropion Column Temperature: 0 C Wash Solvent: 0/0 /acetonitrile Purge Solvent: 0/0 /acetonitrile ACQUITY UPLC -ass with 0.0 0. Compound. Bupropion (pk a = 7.9) 0.0 0. 0.0 0. 0.0 0.0 Peak width (.%) =. seconds USP tailing factor =.7 0.0 0..0..0..0 min 7 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA Analaysis of ozapine Impurities Using ACQUITY CS Columns LC CDITIS ACQUITY CS Phenyl-exyl,. x 0 mm,.7 μm Part umber: 8000 Mobile Phase A: Mobile Phase B: acetonitrile Mobile Phase C: % formic acid in Time Flow (min) (ml/min) %A %B %C Curve μl 80/0 methanol/ Sample Concentration: 00 µg/ml (impurities present at ~0.%) Column Temperature: 0 C Wash Solvent: Purge Solvent: Initial 0. 90 Initial.0 0. 0.0 0. 0 9. 0. 90 8.0 0. 90 0/0 /acetonitrile 0/0 /acetonitrile ACQUITY UPLC -ass with and SQD MS Conditions Capillary:.0 kv (ES + ) Cone: Extractor: 0 V V Desolvation Temperature: 0 C Source Temperature: 0 C Desolvation Gas: Scan Range: Scan Rate: 8-Chloro--(piperazin--yl)-dibenzo[b,e][,]-diazepine 800 L/hr 00 to 0 m/z 000 Da/sec ozapine -[-[(-Amino--chlorophenyl)amino] benzoyl]--methylpiperazine,'-(piperazine-,-diyl) bis(8-chloro--dibenzo [b,e][,]diazepine) 8-Chloro-,0-dihydro- -dibenzo[b,e][,] diazepin--one Intensity Intensity Intensity Intensity 0.0 0 UV nm - 0 min.0 x 0.0 x 0 0.0 x 0.0 x 0 0.0 x 0.0 x 0 0.0 x 0.0 x 0 Extracted Ion Chromatogram at m/z. Extracted Ion Chromatogram at m/z. Extracted Ion Chromatogram at m/z 9. Extracted Ion Chromatogram at m/z.0. 8-Chloro--(piperazin--yl)--dibenzo[b,e][,]-diazepine. ozapine. -[-[(-Amino--chlorophenyl)amino]benzoyl]- -methylpiperazine.,'-(piperazine-,-diyl)bis(8-chloro--dibenzo[b,e] [,]diazepine). 8-Chloro-,0-dihydro--dibenzo[b,e][,]diazepin--one 0 0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation. 8

LC CDITIS Part umber: 800 Mobile Phase A: Mobile Phase B: ACQUITY CS Fluoro-Phenyl,. x 0 mm,.7 μm 0.% phosphoric acid in acetonitrile Initial 0. 98.00 0. 98.0 0. 98. 0. 98.00 0. 98 μl Column Temperature: 0 C Weak eedle Wash: Strong eedle Wash: Filter Time Constant: Time (min) 9/ /acetonitrile 9/ acetonitrile/ UV @ 0 nm 0 points/sec 0. sec Flow (ml/min) ACQUITY UPLC System with %A %B Curve Analysis of Food Additives Using ACQUITY CS Columns p-ydroxybenzoic acid Dehydroacetic acid S Saccharin Sorbic acid C Methyl paraben ACQUITY CS WA 0.0 0.0. p-ydroxybenzoic acid (0 µg/ml). Sorbic acid (0 µg/ml). Dehydroacetic acid (00 µg/ml). Methyl paraben ( µg/ml). Saccharin (00 µg/ml) 0.0 0.0 0.0 0..0..0..0..0..0 min 9 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA Analysis of Formic and Acetic Acids Using ACQUITY CS Columns LC CDITIS ACQUITY CS C 8,. x 00 mm,.7 μm Part umber: 80097 Isocratic Mobile Phase: 0.% phosphoric acid in Flow Rate: 0. ml/min μl Sample Concentration: 0.0% Column Temperature: 0 C Weak eedle Wash: 9/ /acetonitrile Strong eedle Wash: 9/ acetonitrile/ UV @ 0 nm 0 points/sec Filter Time Constant: 0. sec ACQUITY UPLC System with Formic acid Acetic acid 0.07 0.0. Formic acid. Acetic acid 0.0 0.0 0.0 0.0 0.0 0.0 0. 0. 0. 0. 0. 0. 0.7 0.8 0.9.0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation. 0

LC CDITIS ACQUITY CS C 8,. x 0 mm,.7 μm Part umber: 8009 Mobile Phase A: 0.% ammonium hydroxide in Mobile Phase B: acetonitrile Time Flow (min) (ml/min) %A %B Curve μl Sample Concentration: mg/ml of mirtazapine USP resolution standard Column Temperature C Weak eedle Wash: Strong eedle Wash: Filter Time Constant: Initial 0.7 9 Initial. 0.7 78 7. 0.7 78 7. 0.7 9 8.0 0.7 9 0/0 acetonitrile/ 0/0 /acetonitrile 0/0 acetonitrile/ UV @ 90 nm 0 points/sec 0. sec ACQUITY UPLC System with Analysis of Mirtazapine Impurities Using ACQUITY CS Columns Mirtazapine Impurity A Mirtazapine Impurity D Mirtazapine Impurity B Mirtazapine Impurity C Mirtazapine Impurity E ACQUITY CS WA8 Mirtazapine Impurity F Mirtazapine 0.0 8. Mirtazapine Impurity A (0.%). Mirtazapine Impurity B (0.0%). Mirtazapine Impurity C or F (0.09%). Mirtazapine Impurity D (0.%). Mirtazapine (98.8%). Unknown impurity (0.08%) 7. Mirtazapine Impurity E (0.%) 8. Mirtazapine Impurity C or F (0.%) 7 8 0 0.0..0. min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA7 Analysis of onsteroidal Anti-Inflammatory Drugs (SAIDS) Using ACQUITY CS Columns LC CDITIS ACQUITY CS Phenyl-exyl,. x 0 mm,.7 μm Part umber: 8000 Mobile Phase A: Mobile Phase B: acetonitrile Mobile Phase C: % formic acid in Time Flow (min) (ml/min) %A %B %C Curve Tolmetin C Initial 0. 70 Initial.0 0. 80.0 0. 0 9. 0. 70 0.0 0. 70 Fenoprofen C Ibuprofen μl Column Temperature: 0 C Wash Solvent: Purge Solvent: 0/0 /acetonitrile 0/0 /acetonitrile UV @ 70 nm 0 points/sec C aproxen C C Diclofenac Filter Time Constant: 0. sec ACQUITY UPLC -ass System with C C Indomethacin 0.. Tolmetin (0 µg/ml) 0.. aproxen (0 µg/ml). Fenoprofen (0 µg/ml) 0.. Ibuprofen (00 µg/ml) 0.0. Indomethacin (0 µg/ml). Diclofenac (0 µg/ml) 0.08 0.0 0.0 0.0 0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

LC CDITIS ACQUITY CS C 8,. x 0 mm,.7 μm Part umber: 80098 Mobile Phase: 0.% phosphoric acid in Isocratic Flow Rate: 0. ml/min to μl Sample Concentration: µg/ml (0 µg/ml for lactic acid) (0 µg/ml for lactic acid) Column Temperature: C Weak eedle Wash: 9/ /acetonitrile Strong eedle Wash: 9/ acetonitrile/ UV @ 0 nm 0 points/sec Filter Time Constant: 0. sec ACQUITY UPLC System with Sample Preparation Procedure: Samples were filtered through a 0. μm PTFE syringe filter and injected directly. Analysis of rganic Acids Using ACQUITY CS Columns DL-Tartaric acid Lactic Acid Succinic Acid L-Malic acid Acetic Acid C C C Citric Acid ACQUITY CS WA9 0.08 0.0 0.0 0.0-0.0 0.0 0.08 Vitamin-fortified (grape flavor). DL-Tartaric acid. L-Malic acid. Lactic Acid. Acetic Acid. Succinic Acid. Citric Acid 0.0 0.0 0.0 Lemon-lime sports drink 0.0 0.0 0.0 Standard mix 0 7 8 9 0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA8 Analysis of Paroxetine Impurities Using ACQUITY CS Columns LC CDITIS ACQUITY CS Fluoro-Phenyl,. x 00 mm,.7 μm Part umber: 800 Mobile Phase A: Mobile Phase B: methanol Mobile Phase C: % acetic acid in Time Flow (min) (ml/min) %A %B %C Curve Pre-Injector volume: 00 µl μl Sample Concentration: paroxetine at 0. mg/ml; impurities at Column Temperature: 0 C Wash Solvent: Purge solvent: Filter Time Constant: Initial 0. 8 0 Initial.0 0. 7 0.0 0. 7 0. 0. 8 0.0 0. 8 0 mg/ml each 0/0 /acetonitrile 0/0 /acetonitrile UV @ 9 nm 0 points/sec 0. sec ACQUITY UPLC -ass System with F Paroxetine trans--phenyl--[[,-(methylenedioxy) phenoxy]methyl]piperidine F F cis-paroxetine (S-trans)--Methyl--[(,-benzodioxol--yloxy) methyl]--(-fluorophenyl)piperidine. trans--phenyl--[(,-methylenedioxy) phenoxymethyl]-piperidine hydrochloride. cis-paroxetine. Paroxetine hydrochloride. (S-trans)--Methyl--[(,-benzodioxol-- yloxy)methyl]--(-fluorophenyl)piperidine 0 - - - 0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

LC CDITIS Part umber: 800 Mobile Phase A: Mobile Phase B: Mobile Phase C: ACQUITY CS Fluoro-Phenyl,. x 00 mm,.7 μm methanol Pre-Injector volume: 00 µl % acetic acid in μl Sample Concentration: µg/ml each Column Temperature: 0 C Wash Solvent: Purge Solvent: Time (min) Flow (ml/min) 0/0 /acetonitrile 0/0 /acetonitrile ACQUITY UPLC -ass System with SQD %A %B %C Curve Initial 0. 8 0 Initial.0 0. 7 0.0 0. 7 0. 0. 8 0.0 0. 8 0 Analysis of Paroxetine Isomers Using ACQUITY CS Columns MS Conditions Capillary:.0 kv (ES + ) Cone: 0 V Extractor: V Desolvation Temperature: 0 C Source Temperature: 0 C Desolvation Gas: 800 L/hr Scan Range: 00 to 00 m/z Scan Rate: 000 Da/sec F cis-paroxetine F (+)-trans-paroxetine ACQUITY CS CS Columns WA9 8x0 7x0. cis-paroxetine. (+)-trans-paroxetine x0 x0 Intensity x0 x0 x0 x0 0 0 Extracted ion chromatogram at m/z 0. 7 8 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA0 Analysis of Pharmaceutical Test Mix on ACQUITY CS Columns LC CDITIS Columns: ACQUITY CS C 8,. x 0 mm,.7 μm Mobile Phase A: Mobile Phase B: Mobile Phase C: Part umber: 8009 ACQUITY CS Phenyl-exyl,. x 0 mm,.7 μm Part umber: 8000 ACQUITY CS Fluoro-Phenyl,. x 0 mm,.7 μm Part umber: 800 acetonitrile % formic acid in Time (min) μl Flow (ml/min) %A %B %C Curve Initial 0. 90 Initial.0 0. 0 9.0 0. 0 9. 0. 90 0.0 0. 90 F Triamcinolone -Amino-7-chloro--oxo- -[]benzopyrano[,-b] pyridine--carbonitrile 8-Bromoguanosine Acetanilide Br ydrocortisone -Aminofluoranthene Column Temperature: 0 C Wash Solvent: Purge Solvent: 0/0 /acetonitrile 0/0 /acetonitrile UV @ nm Perylene Filter Time Constant: 0 points/sec 0. sec ACQUITY UPLC -ass System with α-methyl-7αhydroxyprogesterone Br -Bromofluorene aphtho[,-a]pyrene 0. 0.0 0.0 ACQUITY CS C8 8 7 8 9 0. 8-Bromoguanosine (. µg/ml). Acetanilide (.7 µg/ml) 0. 0.0 0.0 ACQUITY CS Phenyl-exyl 7 8 9 0. Triamcinolone (. µg/ml). ydrocortisone (. µg/ml). -Amino-7-chloro--oxo--[]benzopyrano[,-b]pyridine--carbonitrile (. µg/ml). -Aminofluoranthene (. µg/ml) 7. α-methyl-7α-hydroxyprogesterone ( µg/ml) 0. 0.0 0.0 ACQUITY CS Fluoro-Phenyl 7 8 9 0 8. -Bromofluorene ( µg/ml) 9. Perylene (. µg/ml) 0. aphtho[,-a]pyrene (. µg/ml) 0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

LC CDITIS Part umber: 800 Mobile Phase A: Mobile Phase B: ACQUITY CS Fluoro-Phenyl,. x 0 mm,.7 μm 0.% formic acid in acetonitrile Time (min) Flow (ml/min) %A %B Curve Analysis of Statin Drugs Using ACQUTY CS Columns Structures a+ C ACQUITY CS CS Columns WA7 Initial 0. 9 Initial.00 0. 0 70.0 0. 9. 0. 9.00 0. 9 Pravastatin sodium C μl F Sample Concentration: 0 µg/ml each Column Temperature: 0 C 80/0 methanol/ Atorvastatin Weak eedle Wash: 9/ /acetonitrile Strong eedle Wash: 9/ acetonitrile/ UV @ 8 nm 0 points/sec Lovastatin Filter Time Constant: 0. sec ACQUITY UPLC System with Simvastatin 0.. Pravastatin sodium (Pravachol). Atorvastatin (Lipitor) 0.. Lovastatin (Mevacor). Simvastatin (Zocor) 0.08 0.0 0 min 7 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA Analysis of Sulfa Drugs Using ACQUITY CS Columns LC CDITIS ACQUITY CS Fluoro-Phenyl,. x 00 mm,.7 μm Part umber: 800 Mobile Phase A: 0.% acetic acid in Mobile Phase B: acetonitrile Time Flow (min) (ml/min) %A %B Curve S Sulfanilamide S Sulfathiazole S Initial 0. 9 Initial.00 0. 0 0.0 0. 0 0. 0. 9.00 0. 9 μl S Sulfamerazine S Sulfamethazine Sample Concentration: 0 µg/ml each Column Temperature: 0 C Weak eedle Wash: 9/ /acetonitrile S S C S S Strong eedle Wash: 9/ acetonitrile/ UV @ nm Sulfamethizole Succinylsulfathiazole Filter Time Constant: 0 points/sec 0. sec ACQUITY UPLC System with S S Sulfamethoxazole Sulfasoxazole 0.0. Sulfanilamide. Sulfathiazole 0.. Sulfamerazine. Sulfamethazine 0.0 0. 7 8. Sulfamethizole. Succinylsulfathiazole 7. Sulfamethoxazole 8. Sulfasoxazole 0.0 0.0 0.0 0..0..0..0..0 min 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation. 8

LC CDITIS Part umber: 8009 Mobile Phase A: Mobile Phase B: Mobile Phase C: ACQUITY CS C 8,. x 0 mm,.7 μm acetonitrile % formic acid in μl Sample Concentration: µg/ml each Column Temperature: 0 C Wash Solvent: Purge Solvent: Filter Time Constant: Time (min) 0/0 /acetonitrile 0/0 /acetonitrile UV @ nm 0 points/sec 0. sec Flow (ml/min) ACQUITY UPLC -ass System with and SQD Analysis of Tricyclic Antidepressants Using ACQUITY CS Columns %A %B %C Curve Initial 0. 70 Initial.0 0. 0.0 0. 0 9. 0. 70.0 0. 70 MS Conditions Capillary:.0 kv (ES + ) Cone: 0 V Extractor: V Desolvation Temperature: 0 C Source Temperature: 0 C Desolvation Gas: 800 L/hr Scan Range: 00 to 00 m/z Scan Rate: 000 Da/sec Doxepin Desipramine ACQUITY CS CS Columns WA Imipramine ortriptyline 0.0 8. Doxepin. Desipramine. Imipramine. ortriptyline Amitriptyline 0 0.0 UV 0..0..0 min. Amitriptyline. Trimipramine.0x0 7 Intensity.0x0 7.0x0 7 Trimipramine.0x0 7 MS 0.0 0..0..0 min 9 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation.

ACQUITY CS WA0 Analysis of Veterinary Drugs Using ACQUITY CS Columns LC CDITIS Columns: ACQUITY CS C 8,. x 00 mm,.7 μm Part umber: 80097 Mobile Phase A: Mobile Phase B: acetonitrile Mobile Phase C:.0% formic acid in (p ~.7) μl 0/90 methanol/ Column Temperature: 0 C Wash: % formic acid in ACQUITY UPLC -ass with TQD (MassLynx v..) TQD Conditions Capillary:.00 kv Extractor:.00 V RF: 0.0 V Source Temperature: 0 C Desolvation Temperature: 0 C Cone Gas Flow: 0 L/r Desolvation Gas Flow: 800 L/r Collision Gas Flow: Time (min) Flow (ml/min) 0.0 ml/min %A %B %C Curve Initial 0. 80 Initial. 0. 0.9 0. 0 9.9 0. 0 9.0 0. 80.0 0. 80. 0. 80 7.0 0. 80 Compound MRM transition (m/z) Cone (V) CID (ev) Ciprofloxacin.00>88. 0.00>. 0 Enrofloxacin 0.0>.8 0.0>.9 Erythromycin 7.8>8.8 0 0 7.8>7.9 0 xacillin 0.0>0. 0.0>. xytetracycline.0>..0>.7 0 Penicillin-G.7>0. 0 0.7>7.0 0 Sulfamerazine.8>9.0 0.8>. 0 Sulfamethazine 79.00>9. 0 0 79.00>. 0.0>0. Tetracycline.0>7.80 0 0 0 00 % F 9 Ciprofloxacin xytetracycline S Sulfamerazine S 7 8 Sulfamethazine 0 0 0..0..0..0..0..0..0 min F Enrofloxacin S xacillin. Ciprofloxacin ( µg/ml). Enrofloxacin ( µg/ml). Erythromycin ( µg/ml). xacillin ( µg/ml). xytetracycline ( µg/ml). Penicillin G ( µg/ml) 7. Sulfamerazine ( µg/ml) 8. Sulfamethazine (0. µg/ml) 9. Tetracycline ( µg/ml) C S Penicillin G C Erythromycin C Tetracycline 00 Waters Corporation. Waters, The Science of What s Possible, ACQUITY CS and ACQUITY UPLC are trademarks of Waters Corporation. 0

ACQUITY CS TES

ACQUITY CS TES

ACQUITY CS TES

Sales ffices Austria and European Export (Central South Eastern Europe, CIS and Middle East) 877 8 07 Australia 99 777 Belgium 7 000 Brazil 09-788 Canada 800 7 x0 China 8 879 888 CIS/Russia +97 77 90/90 977 Czech Republic 0 7 8 Denmark 9 8080 Finland 09 9 88 France 0 8 7 00 Germany 9 9 0000 ong Kong 8 9 800 The etherlands 7 08 700 orway 7 8 0 0 Poland 8 9000 Puerto Rico 787 77 8 Singapore 9 700 Spain 9 009 00 Sweden 8 00 Switzerland 7 70 00 Taiwan 88 898 United Kingdom 08 8 00 All other countries: Waters Corporation U.S.A. 08 78 000 800 7 www.s.com ungary 0 08 India and India Subcontinent 9 80 87 900 Ireland 8 00 Italy 9 0 098 Japan 8 7 79 Korea 8 00 800 Mexico 7 00 Waters Corporation. Waters, CS, ACQUITY UPLC, ACQUITY CS, MassLynx and The Science of What s Possible are trademarks of Waters Corporation. June 00 70007E KK-PDF